These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 4059292)
1. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients. Admani AK; Verma S; Cordingley GJ; Harris RI Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292 [TBL] [Abstract][Full Text] [Related]
2. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)]. Podiwinsky F; Mentasti M; Riederer P; Birkmayer W Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602 [TBL] [Abstract][Full Text] [Related]
3. [The L-dopa test in Parkinson's disease]. Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732 [TBL] [Abstract][Full Text] [Related]
4. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M; Miwa H; Kondo T No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758 [TBL] [Abstract][Full Text] [Related]
5. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease]. Rondot P Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964 [No Abstract] [Full Text] [Related]
6. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948 [TBL] [Abstract][Full Text] [Related]
7. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor]. Rabadeau Dumas JL; Rondot P; Cardon P Therapie; 1977; 32(2):161-72. PubMed ID: 898124 [No Abstract] [Full Text] [Related]
8. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease]. Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079 [TBL] [Abstract][Full Text] [Related]
9. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)]. Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I No To Shinkei; 1979 Mar; 31(3):295-304. PubMed ID: 444336 [No Abstract] [Full Text] [Related]
10. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Brannan T; Yahr MD Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study]. Hayek J Schweiz Med Wochenschr; 1977 Apr; 107(14):474-9. PubMed ID: 847450 [TBL] [Abstract][Full Text] [Related]
12. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease. Celesia GG; Wanamaker WM Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661 [TBL] [Abstract][Full Text] [Related]
13. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa]. Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112 [TBL] [Abstract][Full Text] [Related]
14. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine]. Mizuno Y; Yoshida M; Obayashi T; Ueki A Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921 [No Abstract] [Full Text] [Related]
15. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa]. Lombardo L; De la Garza R Arch Invest Med (Mex); 1977; 8(2):123-8. PubMed ID: 907417 [TBL] [Abstract][Full Text] [Related]
16. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment. Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895 [TBL] [Abstract][Full Text] [Related]
17. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K; Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133 [TBL] [Abstract][Full Text] [Related]
18. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)]. Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549 [No Abstract] [Full Text] [Related]
19. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor]. Londoõ R Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729 [TBL] [Abstract][Full Text] [Related]
20. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism. Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]